Aimei Health Technology Co., Ltd. filings document the regulatory record of a Cayman Islands blank-check company with ordinary shares, units and rights registered for Nasdaq trading. The filings describe SPAC mechanics such as trust-account funding, redemption-related timelines, deadline extensions, shareholder voting procedures and amendments to governing documents.
Recent 8-K, proxy and late-filing records also disclose direct financial obligations, unsecured promissory notes used to fund extension payments, capital-structure terms, material agreements, Nasdaq listing-compliance notices, delayed annual-report reporting and governance matters associated with the company's initial business-combination process.
Aimei Health Technology Co., Ltd extended the deadline to complete its initial business combination by one month, moving the termination date from May 6, 2026 to June 6, 2026. To fund this extension, the company deposited an Extension Payment of $34,330.96 into its trust account for public shareholders.
In connection with this move, Aimei Health issued a zero‑interest Promissory Note for $34,330.96 to its sponsor, Aimei Health Ltd, and United Hydrogen Group Inc., with each contributing $17,165.48. The note is due upon completion of the business combination with United Hydrogen and can be converted into private units at $10.00 per unit immediately before closing.
Aimei Health Technology Co., Ltd., a Cayman Islands special purpose acquisition company listed on Nasdaq as AFJK, reports on its blank-check operations for the year ended December 31, 2025 and its efforts to complete an initial business combination.
The SPAC raised $69,690,000 into a U.S. trust account from its December 2023 IPO and concurrent private placement, after selling 6,900,000 public units at $10.00 each and 332,000 private units. It has been granted up to 36 months from the IPO closing to complete a business combination, with monthly extension loans funded by its sponsor and United Hydrogen.
Aimei has signed a definitive Business Combination Agreement with United Hydrogen Group Inc., whose operations are conducted through PRC subsidiaries, and obtained shareholder approval in November 2025. Closing remains subject to multiple conditions, including Nasdaq listing standards, minimum net tangible assets, and completion of a PRC CSRC filing by United Hydrogen under the Trial Measures for overseas offerings, which is under review.
The filing highlights significant legal and operational risks if the combined company’s main operations are in China, including evolving CSRC and cybersecurity oversight, foreign exchange controls, dividend restrictions, and the possibility that PRC authorities could delay, condition, or restrict offshore listings or capital flows, potentially affecting the value and liquidity of AFJK’s ordinary shares.
Aimei Health Technology Co., Ltd reported that Nasdaq notified the company on April 17, 2026 that it is out of compliance with Nasdaq Listing Rule 5250(c)(1) because it has not filed its Form 10-K for the year ended December 31, 2025. The report was due March 31, 2026, and a Form 12b-25 was filed on April 1, 2026. The notice does not immediately affect trading of Aimei’s ordinary shares, rights, or units on Nasdaq, but continued noncompliance could result in delisting.
The company has 60 days from the notice date to either file the annual report or submit a compliance plan, and may receive up to 180 days from the original due date if a plan is accepted. Aimei states it is working diligently to complete and file the Form 10-K and expects to regain compliance.
Aimei Health Technology Co., Ltd extended the deadline to complete its initial business combination by one month, moving the Termination Date from April 6, 2026 to May 6, 2026. To fund this seventeenth extension, the company deposited $34,330.96 into its trust account, equal to the lesser of $80,000 for all outstanding public shares or $0.033 per share for the month.
The extension payment was funded through an unsecured promissory note issued on April 7, 2026 to Aimei Health Ltd and United Hydrogen Group Inc., each providing $17,165.48. The note is non‑interest‑bearing and becomes due when Aimei completes a business combination with United Hydrogen. The payees may instead convert the note into private units at $10.00 per unit, each unit consisting of one ordinary share and a right to receive one‑fifth of one ordinary share.
Aimei Health Technology Co., Ltd notified the SEC that it could not timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 because the review of the annual report could not be completed before the due date. The company submitted a Form 12b-25 notification dated April 1, 2026 and invoked Rule 12b-25 relief.
The filing states the company checked the Rule 12b-25(b) boxes that describe (a) the reasons required more effort, and (b) the intent to file within the calendar extension period provided by the rule. Contact listed: Junheng Xie, CEO, phone +86 13758131392.
Aimei Health Technology Co., Ltd extended the deadline to complete its initial business combination with United Hydrogen Group Inc. by one month, moving the termination date from March 6, 2026 to April 6, 2026. To fund this sixteenth extension, a total of $34,330.96 was deposited into the company’s trust account for public shareholders, calculated as the lesser of $80,000 for all outstanding public shares or $0.033 per outstanding public share for the month.
In connection with the extension, the company issued an unsecured promissory note for $34,330.96 on March 4, 2026 to its sponsor, Aimei Health Ltd, and United Hydrogen Group Inc., with each contributing $17,165.48. The note bears no interest and becomes due when the business combination with United Hydrogen is completed. The payees may convert the note into private units at $10.00 per unit, each unit consisting of one ordinary share and one right to receive one-fifth of one ordinary share, if they notify the company at least two business days before the business combination closes.
Aimei Health Technology Co., Ltd has extended the deadline to complete its initial business combination by one month, moving the termination date from February 6, 2026 to March 6, 2026. To fund this fifteenth monthly extension, an aggregate $34,330.96 was deposited into the company’s trust account for public shareholders.
In connection with this extension, the company issued an unsecured promissory note for $34,330.96 to its sponsor, Aimei Health Ltd, and United Hydrogen Group Inc., each contributing $17,165.48. The note bears no interest and becomes payable when the company consummates its proposed business combination with United Hydrogen. The payees may instead convert the note into private units of Aimei Health at $10.00 per unit immediately before closing, with each unit consisting of one ordinary share and a right to receive one-fifth of one ordinary share.
Mizuho Financial Group, Inc. has filed Amendment No. 3 to its Schedule 13G stating that it now beneficially owns 0 common shares of Aimei Health Technology Co., Ltd., representing 0.0% of the common share class as of 12/31/2025.
The filing reports no sole or shared voting or dispositive power over Aimei’s common shares. Mizuho is identified as a parent holding company, and notes that related entities may have been indirect beneficial owners through a wholly owned subsidiary, Mizuho Securities USA LLC.
Karpus Management, Inc., doing business as Karpus Investment Management, has filed an amended Schedule 13G reporting its beneficial ownership in Aimei Health Technology Co., Ltd. common shares. As of the event date of 12/31/2025, Karpus reports beneficial ownership of 78,075 common shares, representing 1.28% of the class.
Karpus, a New York-based registered investment adviser, reports sole voting and sole dispositive power over all 78,075 shares, with no shared voting or dispositive power. The shares are held in accounts managed by Karpus, and the firm certifies they were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Aimei Health Technology.
Aimei Health Technology Co., Ltd. (AFJK) filed its quarterly report for the period ended September 30, 2025, showing it remains a pre-revenue SPAC earning income from its trust investments. The company reported net income of $352,019 for the quarter and $961,651 for the nine months, driven by $482,171 and $1,546,821 of interest on cash held in the trust account, partially offset by formation and operating costs. As of September 30, 2025, Aimei held $45,443,570 in its trust account and had a working capital deficit of about $2.75 million, with only $2,979 of cash outside the trust. During February 2025, shareholders redeemed 2,904,267 shares for approximately $31.27 million, reducing redeemable shares to 3,995,733. The company has a signed business combination agreement with United Hydrogen, which shareholders later approved, and has repeatedly extended its deadline to complete the merger to December 6, 2025 using unsecured promissory notes from its sponsor and United Hydrogen. Management notes that failure to close a business combination within the allowed period would trigger liquidation, creating substantial doubt about Aimei’s ability to continue as a going concern.